Bayer has released the results from their university and demo trials with ILeVO seed treatment — demonstrating a measured yield benefit across U.S. soybean growing states, despite varying levels of Soybean Sudden Death Syndrome (SDS) and Soybean Cyst Nematode (SCN) pressure.
Topline results from 2011-2016 university trials show that 2016 ILeVO yield increases are on par with the past four-year average of 4.7 bu/A. SDS trials across 21 variety locations report an average yield increase of 4.7 bu/A in 2016. Yield increases were even greater than 10 bu/A at sites with higher levels of disease infestations.
Across soybean growing states, 304 demo trials were executed to measure the ILeVO yield benefit on a range of plots. Side-by-side demos saw an average yield increase of 3 bu/A, while demos with documented visual symptoms showed an average yield benefit of 3.7 bu/A. Even demos without documented visual symptoms of SDS showed an average yield benefit of 2.7 bu/A.
“We’re proud to see that ILeVO is continuing to perform consistently in 2016,” said Jeremiah Mullock, Bayer seed treatment product development. “It’s important to note that our 304 demo trials reported a 76 percent positive response. It shows that the yield benefit appeared across the trials and not just in a few plots. ILeVO is continuing to demonstrate its return value for growers across varying levels of disease pressure.”